CCHT(SZ:000661) Chang Jiang Shang Bao·2025-09-18 08:36Core Viewpoint - Changchun Gaoxin is actively seeking to overcome performance pressure through a collaboration with ALK for the commercialization of allergy immunotherapy products in China [1][2]. Company Overview - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has entered into a partnership with ALK to develop and commercialize house dust mite allergy immunotherapy products in China [1]. - The partnership grants Changchun Jinsai exclusive rights to three ALK products in mainland China until December 31, 2039 [1][2]. Financial Performance - In the first half of 2025, Changchun Jinsai achieved a net profit of 1.108 billion yuan [3]. - Changchun Gaoxin's revenue and net profit for 2024 were 13.466 billion yuan and 2.583 billion yuan, respectively, reflecting year-on-year declines of 7.55% and 43.01% [4]. - For the first half of 2025, the company reported revenue of 6.603 billion yuan, a slight decrease of 0.54%, and a net profit of 983 million yuan, down 42.85% year-on-year [4]. Market Potential - China has the highest number of dust mite allergy patients globally, but the market remains underdeveloped with low penetration rates [2]. - The collaboration with ALK is expected to provide new growth opportunities for Changchun Jinsai [5].